With 1 ETF traded in the U.S. markets, Loncar Cancer Immunotherapy Index ETF gathers total assets under management of $17.68M. The average expense ratio is 0.79%. Loncar Cancer Immunotherapy Index ETF can be found in the following asset class:
Latest ETF to come to market aims to offer unique access to an emerging hot sector only one other ETF focuses on today.
Bloomberg ETF analyst discusses what’s going on with ETFs in 2018.
These funds give investors exposure to niche areas of the market.
The ISE isn’t just an options exchange; it’s now a mostly unseen player in the ETF industry.
This directory provides a comprehensive list of all the new players in the ETF space and their operations.
The hot segment could use more segmentation, Brad Loncar says.